THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high...
Vous n'êtes pas connecté
WEDNESDAY, Dec. 11, 2024 -- For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, results in a high...
THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high...
THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high...
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
Hemogenyx Pharmaceuticals plc, a publicly traded company headquartered in London, announced the opening of the first clinical site for its lead asset,...
THURSDAY, Jan. 9, 2025 -- Among patients with high-risk prostate cancer and no evidence of metastatic disease on conventional imaging,...
THURSDAY, Jan. 9, 2025 -- Among patients with high-risk prostate cancer and no evidence of metastatic disease on conventional imaging,...
London, UK January 07 2025 -- GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy...
London, UK January 07 2025 -- GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy...
A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal behaviors in high-risk...
A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through...